These findings raise the possibility that continuous engagement of NKG2D by tumor-expressed ULBP2 may contribute to functional impairment of CD8+ T cells and reduced efficacy of CD4+CD25+ T cell-targeted immunotherapies, although this remains to be directly demonstrated. The gene discussed is CD8A; the disease is neoplasm.